Literature DB >> 8301648

Diagnostic criteria and genetics of the PEHO syndrome.

M Somer1.   

Abstract

The PEHO syndrome (progressive encephalopathy with oedema, hypsarrhythmia, and optic atrophy) is a recently recognised disorder of unknown biochemical background. Diagnostic features have been found in neuroradiological and neuropathological studies, which show characteristic severe cerebellar atrophy. In combined neuroradiological and ophthalmological studies, 10 out of 21 possible PEHO patients fulfilled the criteria for true PEHO syndrome. All were abnormal at birth showing hypotonia, drowsiness, or poor feeding. Head circumference was normal, but usually dropped to 2 SD below average during the first year of life. Visual fixation was either absent from birth or lost during the first months of life. Nine patients had peripheral oedema in early childhood. The mean age of onset of infantile spasms was 4.9 months. All patients were extremely hypotonic and no motor milestones were reached. Patellar reflexes were brisk. Brain stem and somatosensory evoked potentials were abnormal in each case studied, cortical responses of somatosensory evoked potentials could not be elicited, and motor conduction velocities became delayed with age. Altogether 19 PEHO patients were found in 14 Finnish families. Autosomal recessive inheritance is likely.

Entities:  

Mesh:

Year:  1993        PMID: 8301648      PMCID: PMC1016602          DOI: 10.1136/jmg.30.11.932

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  6 in total

1.  Progressive encephalopathy with edema, hypsarrhythmia, and optic atrophy (PEHO syndrome).

Authors:  R Salonen; M Somer; M Haltia; M Lorentz; R Norio
Journal:  Clin Genet       Date:  1991-04       Impact factor: 4.438

Review 2.  Hereditary diseases in Finland; rare flora in rare soul.

Authors:  R Norio; H R Nevanlinna; J Perheentupa
Journal:  Ann Clin Res       Date:  1973-06

3.  Infantile cerebello-optic atrophy. Neuropathology of the progressive encephalopathy syndrome with edema, hypsarrhythmia and optic atrophy (the PEHO syndrome).

Authors:  M Haltia; M Somer
Journal:  Acta Neuropathol       Date:  1993       Impact factor: 17.088

4.  Variation of growth in height and weight of children. II. After infancy.

Authors:  R Sorva; S Lankinen; E M Tolppanen; J Perheentupa
Journal:  Acta Paediatr Scand       Date:  1990-05

5.  PEHO syndrome (progressive encephalopathy with edema, hypsarrhythmia, and optic atrophy): neuroradiologic findings.

Authors:  M Somer; O Salonen; H Pihko; R Norio
Journal:  AJNR Am J Neuroradiol       Date:  1993 Jul-Aug       Impact factor: 3.825

6.  Carbohydrate deficient serum transferrin in a new systemic hereditary syndrome.

Authors:  H Stibler; J Jaeken
Journal:  Arch Dis Child       Date:  1990-01       Impact factor: 3.791

  6 in total
  18 in total

Review 1.  The Finnish Disease Heritage III: the individual diseases.

Authors:  Reijo Norio
Journal:  Hum Genet       Date:  2003-03-08       Impact factor: 4.132

2.  Linkage disequilibrium mapping in isolated populations: the example of Finland revisited.

Authors:  A de la Chapelle; F A Wright
Journal:  Proc Natl Acad Sci U S A       Date:  1998-10-13       Impact factor: 11.205

Review 3.  De novo dominant variants affecting the motor domain of KIF1A are a cause of PEHO syndrome.

Authors:  Sylvie Langlois; Maja Tarailo-Graovac; Bryan Sayson; Britt Drögemöller; Anne Swenerton; Colin Jd Ross; Wyeth W Wasserman; Clara Dm van Karnebeek
Journal:  Eur J Hum Genet       Date:  2015-10-21       Impact factor: 4.246

Review 4.  Clinical review of genetic epileptic encephalopathies.

Authors:  Grace J Noh; Y Jane Tavyev Asher; John M Graham
Journal:  Eur J Med Genet       Date:  2012-01-25       Impact factor: 2.708

5.  PEHO syndrome caused by compound heterozygote variants in ZNHIT3 gene.

Authors:  Katrin Õunap; Kai Muru; Eve Õiglane-Shlik; Pilvi Ilves; Sander Pajusalu; Imbi Kuus; Monica H Wojcik; Tiia Reimand
Journal:  Eur J Med Genet       Date:  2019-04-29       Impact factor: 2.708

6.  Serial MR imaging, diffusion tensor imaging, and MR spectroscopic findings in a child with progressive encephalopathy, edema, hypsarrhythmia, and optic atrophy (PEHO) syndrome.

Authors:  T A G M Huisman; A Klein; B Werner; T Straube; E Boltshauser
Journal:  AJNR Am J Neuroradiol       Date:  2006-08       Impact factor: 3.825

7.  Selenoprotein biosynthesis defect causes progressive encephalopathy with elevated lactate.

Authors:  Anna-Kaisa Anttonen; Taru Hilander; Tarja Linnankivi; Pirjo Isohanni; Rachel L French; Yuchen Liu; Miljan Simonović; Dieter Söll; Mirja Somer; Dorota Muth-Pawlak; Garry L Corthals; Anni Laari; Emil Ylikallio; Marja Lähde; Leena Valanne; Tuula Lönnqvist; Helena Pihko; Anders Paetau; Anna-Elina Lehesjoki; Anu Suomalainen; Henna Tyynismaa
Journal:  Neurology       Date:  2015-06-26       Impact factor: 9.910

8.  PEHO Syndrome May Represent Phenotypic Expansion at the Severe End of the Early-Onset Encephalopathies.

Authors:  Pawel Gawlinski; Renata Posmyk; Tomasz Gambin; Danuta Sielicka; Monika Chorazy; Beata Nowakowska; Shalini N Jhangiani; Donna M Muzny; Monika Bekiesinska-Figatowska; Jerzy Bal; Eric Boerwinkle; Richard A Gibbs; James R Lupski; Wojciech Wiszniewski
Journal:  Pediatr Neurol       Date:  2016-04-09       Impact factor: 3.372

9.  Dyschromatosis ptychotropica: an unusual pigmentary disorder in a boy with epileptic encephalopathy and progressive atrophy of the central nervous system-a novel entity?

Authors:  Ingo Helbig; Regina Fölster-Holst; Jochen Brasch; Ingrid Hausser; Andreas van Baalen; Hiltrud Muhle; Karsten Alfke; Almuth Caliebe; Ulrich Stephani; Rudolf Happle
Journal:  Eur J Pediatr       Date:  2009-08-26       Impact factor: 3.183

10.  A homozygous IER3IP1 mutation causes microcephaly with simplified gyral pattern, epilepsy, and permanent neonatal diabetes syndrome (MEDS).

Authors:  Ghada M H Abdel-Salam; Ashleigh E Schaffer; Maha S Zaki; Tracy Dixon-Salazar; Inas S Mostafa; Hanan H Afifi; Joseph G Gleeson
Journal:  Am J Med Genet A       Date:  2012-09-18       Impact factor: 2.802

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.